ASMB (Assembly Biosciences) Additional Paid-In Capital: $1,151.24 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASMB Assembly Biosciences Inc ASMB
34 GF Score
Price $34.38
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Additional Paid-In Capital?

Assembly Biosciences ASMB +2.54% 34 Additional Paid-In Capital is $1,151.24 Mil as of Jun. 2026. GuruFocus rates ASMB with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.


Assembly Biosciences's quarterly additional paid-in capital increased from Dec. 2025 ($1,038.82 Mil) to Mar. 2026 ($1,040.09 Mil) and increased from Mar. 2026 ($1,040.09 Mil) to Jun. 2026 ($1,151.24 Mil).

Assembly Biosciences's annual additional paid-in capital increased from Dec. 2023 ($826.92 Mil) to Dec. 2024 ($859.49 Mil) and increased from Dec. 2024 ($859.49 Mil) to Dec. 2025 ($1,038.82 Mil).

Assembly Biosciences Additional Paid-In Capital Related Terms

Assembly Biosciences Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Additional Paid-In Capital Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 800.73 807.98 826.92 859.49 1,038.82

Assembly Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 863.31 1,036.91 1,038.82 1,040.09 1,151.24
ASMB
34GF Score
Assembly Biosciences Inc ASMB
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $1,151.24 Mil mean?
Assembly Biosciences (ASMB) has a Additional Paid-In Capital of $1,151.24 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Additional Paid-In Capital too high?
Assembly Biosciences' current Additional Paid-In Capital is $1,151.24 Mil. Overall, Assembly Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Additional Paid-In Capital compare to ZURA and ARVN?
Assembly Biosciences' Additional Paid-In Capital of $1,151.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Additional Paid-In Capital is $1,151.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Additional Paid-In Capital of $1,151.24 Mil. The current Additional Paid-In Capital is $1,151.24 Mil. Assembly Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Additional Paid-In Capital is $1,151.24 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
34GF Score

Get the complete analysis for ASMB

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.38
Price